🔗 Visit the ClinicalTrials.gov page for NCT01033721
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. | Oncotarget | 2012 | 1.96 |
| 2 | Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. | Nat Rev Drug Discov | 2012 | 1.52 |
| 3 | Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. | Invest Ophthalmol Vis Sci | 2009 | 0.92 |
| 4 | Diabetic macular edema: current and emerging therapies. | Middle East Afr J Ophthalmol | 2012 | 0.90 |
| 5 | RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. | Anticancer Drugs | 2016 | 0.76 |